138 related articles for article (PubMed ID: 8627903)
1. Thrombolysis with prourokinase versus urokinase: an in vitro comparison.
Fox D; Ouriel K; Green RM; Stoughton J; Riggs P; Cimino C
J Vasc Surg; 1996 Apr; 23(4):657-66. PubMed ID: 8627903
[TBL] [Abstract][Full Text] [Related]
2. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.
Ouriel K; Kandarpa K; Schuerr DM; Hultquist M; Hodkinson G; Wallin B
J Vasc Interv Radiol; 1999 Sep; 10(8):1083-91. PubMed ID: 10496712
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
[TBL] [Abstract][Full Text] [Related]
4. Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction.
Gulba DC; Fischer K; Barthels M; Polensky U; Reil GH; Daniel WG; Welzel D; Lichtlen PR
Am J Cardiol; 1989 May; 63(15):1025-31. PubMed ID: 2495709
[TBL] [Abstract][Full Text] [Related]
5. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
[TBL] [Abstract][Full Text] [Related]
6. Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Wegner CD; Cox BF
Thromb Haemost; 1999 Feb; 81(2):301-5. PubMed ID: 10064010
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
8. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
9. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.
Weaver WD; Hartmann JR; Anderson JL; Reddy PS; Sobolski JC; Sasahara AA
J Am Coll Cardiol; 1994 Nov; 24(5):1242-8. PubMed ID: 7930246
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging.
Takano K; Carano RA; Tatlisumak T; Meiler M; Sotak CH; Kleinert HD; Fisher M
Neurology; 1998 Apr; 50(4):870-5. PubMed ID: 9566365
[TBL] [Abstract][Full Text] [Related]
11. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
12. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
[TBL] [Abstract][Full Text] [Related]
13. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
Bode C; Eberle T; Runge M; Haber E; Kübler W
Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
[No Abstract] [Full Text] [Related]
14. [Thrombolytics and their use].
Alessi MC; Juhan-Vague I
Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
[TBL] [Abstract][Full Text] [Related]
15. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
Collen D; Stassen JM; Verstraete M
J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
[TBL] [Abstract][Full Text] [Related]
16. [Incidence of residual thrombi following successful thrombolytic therapy in acute myocardial infarct and their significance for the rate of early re-occlusion. A report of a multicenter dose-finding study for thrombolytic therapy with urokinase preactivated natural prourokinase (TCL 598)].
Gulba DC; Bode C; Topp J; Höpp HW; Westhoff-Bleck M; Rafflenbeul W; Lichtlen PR
Z Kardiol; 1990 Apr; 79(4):279-85. PubMed ID: 2113330
[TBL] [Abstract][Full Text] [Related]
17. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
Fry ET; Mack DL; Sobel BE
Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
[TBL] [Abstract][Full Text] [Related]
18. Efficient renaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in Escherichia coli as inclusion bodies.
Orsini G; Brandazza A; Sarmientos P; Molinari A; Lansen J; Cauet G
Eur J Biochem; 1991 Feb; 195(3):691-7. PubMed ID: 1847867
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.
Credo RB; Burke SE
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):8S-18S. PubMed ID: 8770836
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
